XOMA Corporation (XOMA)
USD 18.76
(-2.44%)
USD 18.76
(-2.44%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -39.36 Million USD | -23.35% |
| 2022 | -16.84 Million USD | -202.19% |
| 2021 | 16.51 Million USD | 22.06% |
| 2020 | 13.81 Million USD | 21752.38% |
| 2019 | 1.85 Million USD | 99.41% |
| 2018 | -12.48 Million USD | -149.13% |
| 2017 | 20.78 Million USD | 138.92% |
| 2016 | -48.81 Million USD | -61.0% |
| 2015 | -15.3 Million USD | 56.9% |
| 2014 | -32.14 Million USD | -37.66% |
| 2013 | -116.86 Million USD | -19.93% |
| 2012 | -62.62 Million USD | -69.33% |
| 2011 | -24.9 Million USD | 53.34% |
| 2010 | -62.62 Million USD | -361.42% |
| 2009 | 17.99 Million USD | 176.82% |
| 2008 | -31.9 Million USD | -817.52% |
| 2007 | 4.19 Million USD | 112.29% |
| 2006 | -34.51 Million USD | 51.54% |
| 2005 | -36.02 Million USD | 3.38% |
| 2004 | -73.16 Million USD | -36.13% |
| 2003 | -53.54 Million USD | -76.15% |
| 2002 | -29.95 Million USD | -9.97% |
| 2001 | -26.07 Million USD | 17.47% |
| 2000 | -31.28 Million USD | 24.85% |
| 1999 | -44 Million USD | -29.89% |
| 1998 | -41.3 Million USD | -110.91% |
| 1997 | -15.2 Million USD | 34.78% |
| 1996 | -26.2 Million USD | 6.99% |
| 1995 | -23.4 Million USD | 11.4% |
| 1994 | -31 Million USD | 13.52% |
| 1993 | -31.9 Million USD | -26.79% |
| 1992 | -35.9 Million USD | 41.79% |
| 1991 | -39.3 Million USD | -71.62% |
| 1990 | -22.9 Million USD | -7.51% |
| 1989 | -21.3 Million USD | -58.96% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -7 Million USD | 73.9% |
| 2024 Q2 | -1.07 Million USD | 78.66% |
| 2023 FY | - USD | -23.35% |
| 2023 Q1 | -1.68 Million USD | 71.5% |
| 2023 Q3 | -5.84 Million USD | -86.08% |
| 2023 Q4 | -5.45 Million USD | 6.59% |
| 2023 Q2 | -3.13 Million USD | -86.85% |
| 2022 Q3 | -4.36 Million USD | 9.45% |
| 2022 Q1 | -2.06 Million USD | -106.9% |
| 2022 Q2 | -4.82 Million USD | -133.38% |
| 2022 FY | - USD | -202.19% |
| 2022 Q4 | -5.89 Million USD | -34.94% |
| 2021 Q2 | -3.06 Million USD | 52.31% |
| 2021 Q1 | -6.42 Million USD | -127.85% |
| 2021 FY | - USD | 22.06% |
| 2021 Q4 | 29.93 Million USD | 995.45% |
| 2021 Q3 | -3.34 Million USD | -9.18% |
| 2020 Q2 | -3.14 Million USD | 43.95% |
| 2020 Q1 | -5.61 Million USD | -50.11% |
| 2020 FY | - USD | 21752.38% |
| 2020 Q3 | -2.67 Million USD | 14.88% |
| 2020 Q4 | 23.05 Million USD | 961.08% |
| 2019 Q4 | -3.73 Million USD | -195.07% |
| 2019 FY | - USD | 99.41% |
| 2019 Q1 | 2.95 Million USD | 234.06% |
| 2019 Q2 | -3.67 Million USD | -224.49% |
| 2019 Q3 | 3.93 Million USD | 206.99% |
| 2018 Q1 | -3.65 Million USD | -195.8% |
| 2018 Q2 | -923 Thousand USD | 74.77% |
| 2018 Q3 | -3.24 Million USD | -251.68% |
| 2018 Q4 | -2.2 Million USD | 32.16% |
| 2018 FY | - USD | -149.13% |
| 2017 Q2 | 3.15 Million USD | 137.17% |
| 2017 Q1 | -8.48 Million USD | 29.22% |
| 2017 FY | - USD | 138.92% |
| 2017 Q4 | -1.23 Million USD | -104.3% |
| 2017 Q3 | 28.76 Million USD | 812.66% |
| 2016 Q1 | -13.49 Million USD | -144.86% |
| 2016 FY | - USD | -61.0% |
| 2016 Q4 | -11.98 Million USD | -4.32% |
| 2016 Q3 | -11.48 Million USD | 34.54% |
| 2016 Q2 | -17.54 Million USD | -30.05% |
| 2015 FY | - USD | 56.9% |
| 2015 Q1 | -22.1 Million USD | -17.99% |
| 2015 Q3 | -20.67 Million USD | 8.42% |
| 2015 Q2 | -22.57 Million USD | -2.14% |
| 2015 Q4 | 30.08 Million USD | 245.49% |
| 2014 Q2 | -18.35 Million USD | 20.06% |
| 2014 FY | - USD | -37.66% |
| 2014 Q1 | -22.96 Million USD | -45.8% |
| 2014 Q3 | -19.98 Million USD | -8.9% |
| 2014 Q4 | -18.73 Million USD | 6.27% |
| 2013 Q1 | -10.41 Million USD | 16.7% |
| 2013 Q2 | -13.35 Million USD | -28.2% |
| 2013 FY | - USD | -19.93% |
| 2013 Q3 | -16.34 Million USD | -22.39% |
| 2013 Q4 | -15.74 Million USD | 3.63% |
| 2012 Q2 | -11.66 Million USD | -25.11% |
| 2012 FY | - USD | -69.33% |
| 2012 Q4 | -12.5 Million USD | 16.32% |
| 2012 Q3 | -14.94 Million USD | -28.14% |
| 2012 Q1 | -9.32 Million USD | 13.23% |
| 2011 Q1 | -5.76 Million USD | 60.73% |
| 2011 Q2 | -6.49 Million USD | -12.66% |
| 2011 Q3 | -5.56 Million USD | 14.27% |
| 2011 Q4 | -10.74 Million USD | -92.91% |
| 2011 FY | - USD | 53.34% |
| 2010 Q3 | -15.25 Million USD | 10.17% |
| 2010 FY | - USD | -361.42% |
| 2010 Q1 | -14.42 Million USD | -487.43% |
| 2010 Q4 | -14.67 Million USD | 3.76% |
| 2010 Q2 | -16.97 Million USD | -17.71% |
| 2009 Q4 | 3.72 Million USD | -56.08% |
| 2009 Q3 | 8.47 Million USD | 210.58% |
| 2009 FY | - USD | 176.82% |
| 2009 Q2 | -7.66 Million USD | -140.54% |
| 2009 Q1 | 18.9 Million USD | 37.76% |
| 2008 FY | - USD | -817.52% |
| 2008 Q4 | 13.72 Million USD | 187.19% |
| 2008 Q3 | -15.74 Million USD | 10.02% |
| 2008 Q2 | -17.49 Million USD | -58.97% |
| 2008 Q1 | -11 Million USD | -58.69% |
| 2007 FY | - USD | 112.29% |
| 2007 Q4 | -6.93 Million USD | -129.12% |
| 2007 Q3 | 23.81 Million USD | 501.8% |
| 2007 Q2 | -5.92 Million USD | 11.56% |
| 2007 Q1 | -6.7 Million USD | 25.71% |
| 2006 Q1 | -10.21 Million USD | -86.9% |
| 2006 FY | - USD | 51.54% |
| 2006 Q4 | -9.02 Million USD | -14.2% |
| 2006 Q3 | -7.9 Million USD | -5.74% |
| 2006 Q2 | -7.47 Million USD | 26.87% |
| 2005 Q3 | -7.35 Million USD | -4.65% |
| 2005 Q2 | -7.03 Million USD | 86.26% |
| 2005 FY | - USD | 3.38% |
| 2005 Q1 | -51.15 Million USD | -217.68% |
| 2005 Q4 | -5.46 Million USD | 25.7% |
| 2004 Q3 | -18.83 Million USD | 5.15% |
| 2004 Q1 | -19.27 Million USD | -3.8% |
| 2004 FY | - USD | -36.13% |
| 2004 Q4 | -16.1 Million USD | 14.52% |
| 2004 Q2 | -19.86 Million USD | -3.04% |
| 2003 Q2 | -14.82 Million USD | -25.97% |
| 2003 Q1 | -11.86 Million USD | -189.74% |
| 2003 Q4 | -18.35 Million USD | -114.19% |
| 2003 Q3 | -8.5 Million USD | 42.54% |
| 2003 FY | - USD | -76.15% |
| 2002 Q2 | -10.11 Million USD | -73.4% |
| 2002 Q4 | -3.96 Million USD | 65.77% |
| 2002 Q1 | -5.83 Million USD | 19.52% |
| 2002 FY | - USD | -9.97% |
| 2002 Q3 | -12.07 Million USD | -19.4% |
| 2001 Q2 | -6.92 Million USD | 9.12% |
| 2001 Q4 | -7.24 Million USD | 3.22% |
| 2001 FY | - USD | 17.47% |
| 2001 Q1 | -7.62 Million USD | 22.48% |
| 2001 Q3 | -7.49 Million USD | -8.11% |
| 2000 Q4 | -9.83 Million USD | -23.76% |
| 2000 FY | - USD | 24.85% |
| 2000 Q3 | -7.94 Million USD | -3.45% |
| 2000 Q2 | -7.68 Million USD | -15.71% |
| 2000 Q1 | -6.63 Million USD | 19.05% |
| 1999 Q4 | -8.2 Million USD | 29.31% |
| 1999 Q3 | -11.6 Million USD | 7.2% |
| 1999 FY | - USD | -29.89% |
| 1999 Q2 | -12.5 Million USD | 10.71% |
| 1999 Q1 | -14 Million USD | -1066.67% |
| 1998 Q4 | -1.2 Million USD | 91.24% |
| 1998 Q2 | -10.1 Million USD | 9.82% |
| 1998 FY | - USD | -110.91% |
| 1998 Q1 | -11.2 Million USD | -227.27% |
| 1998 Q3 | -13.7 Million USD | -35.64% |
| 1997 Q4 | 8.6 Million USD | 198.88% |
| 1997 Q3 | -8.9 Million USD | 5.32% |
| 1997 Q2 | -9.4 Million USD | -4.44% |
| 1997 Q1 | -9 Million USD | -60.71% |
| 1997 FY | - USD | 34.78% |
| 1996 FY | - USD | 6.99% |
| 1996 Q1 | -7.3 Million USD | -19.67% |
| 1996 Q3 | -8.4 Million USD | -42.37% |
| 1996 Q4 | -5.6 Million USD | 33.33% |
| 1996 Q2 | -5.9 Million USD | 19.18% |
| 1995 Q1 | -6.7 Million USD | 5.63% |
| 1995 FY | - USD | 11.4% |
| 1995 Q4 | -6.1 Million USD | 29.07% |
| 1995 Q3 | -8.6 Million USD | -2.38% |
| 1995 Q2 | -8.4 Million USD | -25.37% |
| 1994 Q3 | -9.3 Million USD | -10.71% |
| 1994 FY | - USD | 13.52% |
| 1994 Q4 | -7.1 Million USD | 23.66% |
| 1994 Q2 | -8.4 Million USD | 7.69% |
| 1994 Q1 | -9.1 Million USD | -1.11% |
| 1993 Q1 | -9.6 Million USD | 5.88% |
| 1993 Q4 | -9 Million USD | 7.22% |
| 1993 Q3 | -9.7 Million USD | 3.96% |
| 1993 Q2 | -10.1 Million USD | -5.21% |
| 1993 FY | - USD | -26.79% |
| 1992 Q4 | -10.2 Million USD | -580.0% |
| 1992 FY | - USD | 41.79% |
| 1992 Q1 | -11.5 Million USD | 24.34% |
| 1992 Q2 | -7.7 Million USD | 33.04% |
| 1992 Q3 | -1.5 Million USD | 80.52% |
| 1991 Q2 | -12.1 Million USD | -39.08% |
| 1991 Q3 | -14.2 Million USD | -17.36% |
| 1991 Q4 | -15.2 Million USD | -7.04% |
| 1991 FY | - USD | -61.41% |
| 1991 Q1 | -8.7 Million USD | 9.38% |
| 1990 Q1 | -4.7 Million USD | 60.17% |
| 1990 Q3 | -8.7 Million USD | -2.35% |
| 1990 Q2 | -8.5 Million USD | -80.85% |
| 1990 FY | - USD | 1.32% |
| 1990 Q4 | -9.6 Million USD | -10.34% |
| 1989 FY | - USD | -75.58% |
| 1989 Q1 | 700 Thousand USD | 103.98% |
| 1989 Q3 | -7.7 Million USD | -20.31% |
| 1989 Q2 | -6.4 Million USD | -1014.29% |
| 1989 Q4 | -11.8 Million USD | -53.25% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Akebia Therapeutics, Inc. | -6.86 Million USD | -473.122% |
| Jaguar Health, Inc. | -33.13 Million USD | -18.807% |
| Keros Therapeutics, Inc. | -152.17 Million USD | 74.134% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 30.645% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 84.758% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | 138.694% |
| ContextLogic Inc. | -324 Million USD | 87.851% |
| MiMedx Group, Inc. | 40.51 Million USD | 197.149% |
| MEI Pharma, Inc. | 26.38 Million USD | 249.212% |
| AlloVir, Inc. | -190.14 Million USD | 79.299% |
| Novavax, Inc. | -487.39 Million USD | 91.924% |
| Aptorum Group Limited | -9.59 Million USD | -310.064% |
| Ardelyx, Inc. | -55.35 Million USD | 28.89% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 77.593% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -1330.524% |
| Vaxcyte, Inc. | -464.88 Million USD | 91.533% |
| Precigen, Inc. | -89.22 Million USD | 55.885% |
| Pharming Group N.V. | 9.87 Million USD | 498.522% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | 75.252% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | -72.929% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | -131.8% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 83.142% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | -119.001% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | -63.247% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | -63.247% |
| Bicycle Therapeutics plc | -183.4 Million USD | 78.538% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 54.977% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | -35.904% |
| Acelyrin, Inc. | -381.52 Million USD | 89.683% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | 7540.832% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | -17.9% |
| Senti Biosciences, Inc. | -61.33 Million USD | 35.826% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | 64.95% |
| AbCellera Biologics Inc. | -192.15 Million USD | 79.516% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | -27.369% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | 76.205% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | -12162.305% |
| Chimerix, Inc. | -92.97 Million USD | 57.663% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | -21.289% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -95.258% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 11.42% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 16.004% |
| Elevation Oncology, Inc. | -41.46 Million USD | 5.076% |
| Alkermes plc | 495.04 Million USD | 107.951% |
| Fortress Biotech, Inc. | -133.64 Million USD | 70.547% |
| Fortress Biotech, Inc. | -133.64 Million USD | 70.547% |
| Agenus Inc. | -145.92 Million USD | 73.026% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | 49.107% |
| Dyadic International, Inc. | -8.22 Million USD | -378.29% |
| ImmuCell Corporation | -2.5 Million USD | -1471.917% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | -13426.46% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | 69.819% |
| Lantern Pharma Inc. | -15.78 Million USD | -149.337% |
| Immix Biopharma, Inc. | -16.13 Million USD | -143.944% |
| Incyte Corporation | 919.42 Million USD | 104.281% |
| IO Biotech, Inc. | -91.22 Million USD | 56.853% |
| Janux Therapeutics, Inc. | -71.02 Million USD | 44.579% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | -97.676% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | 31.396% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | 74.96% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | -368.818% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | 47.387% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 89.641% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 92.71% |
| NextCure, Inc. | -59.03 Million USD | 33.329% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | -294.884% |
| Onconetix, Inc. | -36.7 Million USD | -7.234% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | 1861.163% |
| Opthea Limited | -200.01 Million USD | 80.321% |
| PDS Biotechnology Corporation | -40.08 Million USD | 1.804% |
| PureTech Health plc | -11.62 Million USD | -238.54% |
| Pyxis Oncology, Inc. | -78.49 Million USD | 49.853% |
| Seer, Inc. | -97.88 Million USD | 59.788% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | -305389.608% |
| Clearside Biomedical, Inc. | -23.05 Million USD | -70.709% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | -543.533% |
| VYNE Therapeutics Inc. | -29.25 Million USD | -34.534% |
| Wave Life Sciences Ltd. | -58.79 Million USD | 33.046% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | -65.839% |
| C4 Therapeutics, Inc. | -122.1 Million USD | 67.763% |
| ChromaDex Corporation | -3.89 Million USD | -910.837% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | -471.79% |
| Caribou Biosciences, Inc. | -112.53 Million USD | 65.022% |
| CRISPR Therapeutics AG | -202.7 Million USD | 80.581% |
| Precision BioSciences, Inc. | -32.04 Million USD | -22.845% |
| Fate Therapeutics, Inc. | -172.22 Million USD | 77.146% |
| Innoviva, Inc. | 248.96 Million USD | 115.811% |
| Summit Therapeutics Inc. | 1 Million USD | 4032.268% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | 36.714% |
| Aadi Bioscience, Inc. | -65.36 Million USD | 39.781% |
| ESSA Pharma Inc. | -26.45 Million USD | -48.787% |
| GlycoMimetics, Inc. | -39.12 Million USD | -0.613% |
| GT Biopharma, Inc. | 5.97 Million USD | 758.338% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 80.956% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 145.342% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | 23.15% |
| Alzamend Neuro, Inc. | -9.88 Million USD | -298.123% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 83.365% |
| Aptose Biosciences Inc. | -52.26 Million USD | 24.692% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | 63.467% |
| Soligenix, Inc. | -7.85 Million USD | -401.245% |
| Century Therapeutics, Inc. | -121.2 Million USD | 67.525% |
| Kura Oncology, Inc. | -164.95 Million USD | 76.138% |
| TScan Therapeutics, Inc. | -80.09 Million USD | 50.858% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | -290.264% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | -4009.888% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | -813.483% |
| Autolus Therapeutics plc | -156.77 Million USD | 74.892% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 53.504% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | 42.954% |
| Eterna Therapeutics Inc. | -19.93 Million USD | -97.462% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 79.204% |
| GRI Bio, Inc. | -10.89 Million USD | -261.186% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -771.667% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | 67.869% |
| IGM Biosciences, Inc. | -253.35 Million USD | 84.464% |
| INmune Bio, Inc. | - USD | Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 62.076% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | -3.222% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -156.749% |
| Entero Therapeutics, Inc. | -15.74 Million USD | -150.025% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | 30.756% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | 63.248% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 85.202% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 79.704% |
| Verastem, Inc. | -83.16 Million USD | 52.671% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 22.166% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | 75.123% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | 65.499% |
| Histogen Inc. | -10.5 Million USD | -274.769% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | -175.65% |
| Surrozen, Inc. | -41.13 Million USD | 4.301% |
| Organovo Holdings, Inc. | -14.8 Million USD | -165.852% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 1227477.611% |
| Ovid Therapeutics Inc. | -58.71 Million USD | 32.959% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 23.262% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | -82.748% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | -372.079% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | 76.297% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | 20.091% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | -62.882% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | -161.454% |
| Apollomics, Inc. | -171.74 Million USD | 77.081% |
| Amarin Corporation plc | -50.9 Million USD | 22.67% |
| Mesoblast Limited | -61.33 Million USD | 35.82% |
| Turnstone Biologics Corp. | -56.23 Million USD | 30.003% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | 72.513% |
| Synaptogenix, Inc. | -8.3 Million USD | -373.812% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | -156.614% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | 37.567% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -721.502% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | 9274.457% |
| Exelixis, Inc. | 196.6 Million USD | 120.021% |
| Better Therapeutics, Inc. | -38.26 Million USD | -2.875% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | 72.164% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 92.051% |
| NLS Pharmaceutics AG | -11.79 Million USD | -233.699% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | 16022.109% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | -33.403% |
| Gritstone bio, Inc. | -126.86 Million USD | 68.973% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 39.429% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -884.063% |
| Avid Bioservices, Inc. | -11.48 Million USD | -242.845% |
| Insmed Incorporated | -654.73 Million USD | 93.988% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | -1649.641% |
| MediWound Ltd. | -4.89 Million USD | -704.455% |
| OmniAb, Inc. | -49.73 Million USD | 20.85% |
| Alector, Inc. | -142.89 Million USD | 72.453% |
| Seres Therapeutics, Inc. | -85.43 Million USD | 53.927% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 24.519% |
| Zai Lab Limited | -366.57 Million USD | 89.262% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 86.457% |
| Aura Biosciences, Inc. | -83.69 Million USD | 52.97% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 82.525% |
| Immunic, Inc. | -99.11 Million USD | 60.285% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | 70.106% |
| Veracyte, Inc. | -49.4 Million USD | 20.334% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | -457.225% |
| FibroGen, Inc. | -261.4 Million USD | 84.942% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -253.308% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | -462.208% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | -110.302% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 102.716% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | -54.834% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | 198.676% |
| TG Therapeutics, Inc. | 26.1 Million USD | 250.812% |
| Galecto, Inc. | -37.51 Million USD | -4.912% |
| Calithera Biosciences, Inc. | -38.26 Million USD | -2.867% |
| Fortrea Holdings Inc. | 167.3 Million USD | 123.528% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | 70.687% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | -39.034% |
| XBiotech Inc. | -35.76 Million USD | -10.054% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 39.429% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | 39.675% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | 62.317% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | -53.327% |
| Theravance Biopharma, Inc. | -40.86 Million USD | 3.683% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 92.378% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | 29.737% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -70125.331% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | 66.165% |
| Gain Therapeutics, Inc. | -22.16 Million USD | -77.55% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 83.255% |
| NexImmune, Inc. | -28.16 Million USD | -39.743% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | -612.364% |
| Marker Therapeutics, Inc. | -11.79 Million USD | -233.795% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 100.846% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | -55.017% |
| Scopus BioPharma Inc. | -11.71 Million USD | -236.05% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | 68.722% |
| Ainos, Inc. | -8.77 Million USD | -348.667% |
| Pluri Inc. | -20.22 Million USD | -94.621% |
| Prothena Corporation plc | -190.1 Million USD | 79.295% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | 69.296% |
| Celularity Inc. | -183.94 Million USD | 78.601% |
| Rallybio Corporation | -72.37 Million USD | 45.612% |
| Cue Biopharma, Inc. | -46.05 Million USD | 14.527% |
| MeiraGTx Holdings plc | -57.05 Million USD | 31.007% |
| Omeros Corporation | -163.61 Million USD | 75.942% |
| Humacyte, Inc. | -96.45 Million USD | 59.193% |
| Immunocore Holdings plc | -59.64 Million USD | 34.011% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | -103.19% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | -61.551% |
| Blueprint Medicines Corporation | -474.61 Million USD | 91.706% |
| CalciMedica, Inc. | -34.18 Million USD | -15.131% |
| Cabaletta Bio, Inc. | -73.23 Million USD | 46.252% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | 68.635% |
| Scholar Rock Holding Corporation | -168.45 Million USD | 76.633% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 84.404% |
| Pulmatrix, Inc. | -12.64 Million USD | -211.26% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | -19.402% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | 55.507% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 92.226% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | 61.111% |
| Cytokinetics, Incorporated | -456.68 Million USD | 91.381% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | -17.946% |
| Nutriband Inc. | -5.12 Million USD | -668.522% |
| Protara Therapeutics, Inc. | -43.27 Million USD | 9.036% |
| Vor Biopharma Inc. | -114.37 Million USD | 65.584% |
| Roivant Sciences Ltd. | -996.51 Million USD | 96.05% |
| Evogene Ltd. | -23.2 Million USD | -69.635% |
| ProKidney Corp. | -147.66 Million USD | 73.344% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 39.007% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | -25601.768% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 93.039% |
| CorMedix Inc. | -48.88 Million USD | 19.484% |
| BioLineRx Ltd. | -57.06 Million USD | 31.018% |
| Tango Therapeutics, Inc. | -111.75 Million USD | 64.779% |
| Galectin Therapeutics Inc. | -202 Thousand USD | -19386.139% |
| Atai Life Sciences N.V. | -36.31 Million USD | -8.402% |
| Renovaro Biosciences Inc. | -79.51 Million USD | 50.499% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | 51.592% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 85.713% |
| Sagimet Biosciences Inc. | -30.74 Million USD | -28.048% |
| MediciNova, Inc. | -9.87 Million USD | -298.402% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | 68.746% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -2472.342% |
| GeoVax Labs, Inc. | -26.66 Million USD | -47.596% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 82.505% |
| Biomea Fusion, Inc. | -124.62 Million USD | 68.414% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 88.084% |
| Mereo BioPharma Group plc | -26.05 Million USD | -51.067% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 79.32% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 82.882% |
| Absci Corporation | -95.45 Million USD | 58.765% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | -31.097% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | 63.254% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 83.141% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | -72.225% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 81.061% |
| Allakos Inc. | -189.91 Million USD | 79.274% |
| Imunon, Inc. | -19.87 Million USD | -98.015% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | 63.719% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 136.337% |
| BioAtla, Inc. | -122.24 Million USD | 67.8% |
| NLS Pharmaceutics AG | -11.79 Million USD | -233.699% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | -149.743% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 86.892% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | 5.031% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | 60.342% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 66.543% |
| aTyr Pharma, Inc. | -52.17 Million USD | 24.562% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | 53.037% |
| Akero Therapeutics, Inc. | -148.63 Million USD | 73.517% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 83.219% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | -188.303% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | -389.437% |
| Akari Therapeutics, Plc | -16.8 Million USD | -134.27% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 20958.902% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 108.709% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -516.126% |
| UroGen Pharma Ltd. | -63.83 Million USD | 38.334% |
| Sutro Biopharma, Inc. | -67.91 Million USD | 42.042% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -441.951% |
| Orgenesis Inc. | -60.71 Million USD | 35.172% |
| Entera Bio Ltd. | -8.8 Million USD | -347.092% |
| GH Research PLC | -41.15 Million USD | 4.352% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | -54.246% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | 52.134% |
| Xencor, Inc. | -125.87 Million USD | 68.729% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | -2659.254% |
| Replimune Group, Inc. | -230.19 Million USD | 82.901% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | -95.271% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | -259.733% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -516.126% |
| Portage Biotech Inc. | -18.19 Million USD | -116.287% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -2472.342% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | 62.363% |
| OncoCyte Corporation | -23.12 Million USD | -70.229% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | -248.325% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | -243.568% |
| Purple Biotech Ltd. | -22.22 Million USD | -77.107% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | -514.072% |
| scPharmaceuticals Inc. | -46.06 Million USD | 14.544% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | -121.015% |
| HilleVax, Inc. | -132.46 Million USD | 70.285% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | -270.187% |
| Tharimmune, Inc. | -9.3 Million USD | -323.13% |
| Genprex, Inc. | -31.06 Million USD | -26.727% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 79.01% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | -25.541% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | -5052.094% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | 26184.133% |
| OKYO Pharma Limited | -15.74 Thousand USD | -249883.011% |
| Savara Inc. | -59.13 Million USD | 33.435% |
| Curis, Inc. | -45.13 Million USD | 12.798% |
| Daré Bioscience, Inc. | -30.7 Million USD | -28.209% |
| Carmell Therapeutics Corporation | -15.19 Million USD | -159.111% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | -449.365% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | -47.236% |
| BeiGene, Ltd. | -1.12 Billion USD | 96.5% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | -141.467% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 90.858% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | 56.429% |
| Erasca, Inc. | -121.31 Million USD | 67.553% |
| bluebird bio, Inc. | -167.16 Million USD | 76.453% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -774.953% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 112.686% |
| DBV Technologies S.A. | -85.98 Million USD | 54.221% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -774.953% |
| Moderna, Inc. | -3.28 Billion USD | 98.801% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 7.62% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | -596.919% |
| Molecular Templates, Inc. | 1.43 Million USD | 2852.587% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | 34.234% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 87.935% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | 71.287% |
| Spruce Biosciences, Inc. | -47.36 Million USD | 16.898% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | 71.689% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 80.879% |
| MacroGenics, Inc. | 2.01 Million USD | 2051.512% |
| RenovoRx, Inc. | -11.39 Million USD | -245.584% |
| Adicet Bio, Inc. | -136.53 Million USD | 71.171% |
| Prime Medicine, Inc. | -193.75 Million USD | 79.685% |
| Aditxt, Inc. | -25.45 Million USD | -54.616% |
| Adagene Inc. | -14.95 Million USD | -163.277% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -438.461% |
| Quantum-Si incorporated | -91.8 Million USD | 57.124% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 105.525% |
| Acurx Pharmaceuticals, Inc. | - USD | Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | 131.127% |
| SciSparc Ltd. | -5.28 Million USD | -645.21% |
| Vericel Corporation | 2.86 Million USD | 1474.372% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -41243.164% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | -81.463% |
| Generation Bio Co. | -133.3 Million USD | 70.471% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 52.593% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | 54.242% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 82.693% |
| Invivyd, Inc. | -196.61 Million USD | 79.98% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 89.48% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | -324.397% |
| Spero Therapeutics, Inc. | 27.15 Million USD | 244.958% |
| Artelo Biosciences, Inc. | -10.28 Million USD | -282.713% |
| 2seventy bio, Inc. | -206.41 Million USD | 80.931% |
| ADMA Biologics, Inc. | 5.12 Million USD | 868.789% |
| Clene Inc. | -43.24 Million USD | 8.971% |
| Capricor Therapeutics, Inc. | -23 Million USD | -71.072% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | 18.803% |
| GeoVax Labs, Inc. | -26.66 Million USD | -47.596% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 86.86% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | -7.168% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | 266.979% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | 901.628% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | -21.181% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | 75.151% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 94.248% |
| Evaxion Biotech A/S | -21.4 Million USD | -83.909% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | 40.733% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 81.917% |
| Trevena, Inc. | -35.28 Million USD | -11.545% |
| Surrozen, Inc. | -41.13 Million USD | 4.301% |
| Tyra Biosciences, Inc. | -79.59 Million USD | 50.545% |
| Cingulate Inc. | -22.95 Million USD | -71.497% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | -427.57% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -5.576% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | -378.486% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | 61.51% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | 41.967% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | 32.567% |
| Clearmind Medicine Inc. | -8.71 Million USD | -351.883% |
| Kronos Bio, Inc. | -121.83 Million USD | 67.691% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | 47.053% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -1512.262% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 60.961% |
| Statera Biopharma, Inc. | 38.93 Million USD | 201.097% |
| ImmunityBio, Inc. | -436.18 Million USD | 90.976% |
| Korro Bio, Inc. | -80.9 Million USD | 51.347% |
| Kineta, Inc. | -15.71 Million USD | -150.49% |
| BioVie Inc. | -31.95 Million USD | -23.198% |
| Codexis, Inc. | -49.28 Million USD | 20.131% |
| Celularity Inc. | -183.94 Million USD | 78.601% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 82.23% |
| Celcuity Inc. | -58.3 Million USD | 32.495% |
| Virax Biolabs Group Limited | -6.6 Million USD | -495.569% |
| Cibus, Inc. | -314.58 Million USD | 87.488% |
| Eledon Pharmaceuticals, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | -16.687% |
| IN8bio, Inc. | -28.5 Million USD | -38.093% |
| Kodiak Sciences Inc. | -259.02 Million USD | 84.804% |
| Annexon, Inc. | -141.57 Million USD | 72.197% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | 65.042% |
| Assembly Biosciences, Inc. | -64.19 Million USD | 38.685% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | -40.805% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 82.887% |
| Eyenovia, Inc. | -24.1 Million USD | -63.287% |
| Puma Biotechnology, Inc. | 44.78 Million USD | 187.893% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -12048.765% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | 46.667% |
| Arcellx, Inc. | -64.14 Million USD | 38.636% |
| Cardiff Oncology, Inc. | -45.01 Million USD | 12.556% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | 68.122% |
| Regulus Therapeutics Inc. | -30.88 Million USD | -27.459% |
| Moolec Science SA | -52.07 Million USD | 24.414% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | 23.726% |
| Geron Corporation | -174.78 Million USD | 77.479% |
| LAVA Therapeutics N.V. | -40.41 Million USD | 2.61% |
| Royalty Pharma plc | 1.88 Billion USD | 102.086% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | 67.087% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | -322.146% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | -89.781% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | 76.299% |
| Humacyte, Inc. | -96.45 Million USD | 59.193% |
| Structure Therapeutics Inc. | -102.45 Million USD | 61.583% |
| 89bio, Inc. | -134.46 Million USD | 70.727% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | 50.096% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | 1071.422% |
| Genelux Corporation | -24.16 Million USD | -62.888% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | -16.456% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | 75.92% |
| Notable Labs, Ltd. | -14.4 Million USD | -173.347% |
| Liquidia Corporation | -70.05 Million USD | 43.81% |
| Mustang Bio, Inc. | -48.06 Million USD | 18.103% |
| Immunovant, Inc. | -269.97 Million USD | 85.42% |
| Quantum-Si incorporated | -91.8 Million USD | 57.124% |
| Arbutus Biopharma Corporation | -70.98 Million USD | 44.55% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | -103.864% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 61.414% |
| Acasti Pharma Inc. | -11.3 Million USD | -248.305% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | -76.882% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -156.749% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 81.302% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | -821.753% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | -147.872% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | -36.788% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | -6.298% |
| PepGen Inc. | -83.58 Million USD | 52.906% |
| Moleculin Biotech, Inc. | -29.5 Million USD | -33.412% |
| United Therapeutics Corporation | 1.38 Billion USD | 102.838% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | -71.909% |
| Solid Biosciences Inc. | -93.43 Million USD | 57.872% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | -724.899% |
| Immuneering Corporation | -58.06 Million USD | 32.206% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 1227477.611% |
| Silo Pharma, Inc. | -3.62 Million USD | -985.485% |
| Belite Bio, Inc | -31.52 Million USD | -24.844% |
| XOMA Corporation | -39.36 Million USD | -0.0% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | 41.64% |
| Bionomics Limited | -9.83 Million USD | -300.143% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 53.132% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | -13.743% |
| uniQure N.V. | -253.1 Million USD | 84.448% |
| Cassava Sciences, Inc. | -95.68 Million USD | 58.864% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -438.461% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 69.606% |
| Forte Biosciences, Inc. | -32.47 Million USD | -21.2% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | -388.94% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | -39.488% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -12048.765% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -253.308% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | -147.544% |
| Altimmune, Inc. | -87.93 Million USD | 55.237% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 57.252% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | -13.743% |
| Compugen Ltd. | -12.51 Million USD | -214.493% |
| Peak Bio, Inc. | -1356.23 USD | -2902210.08% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | 19.005% |
| Benitec Biopharma Inc. | -22.49 Million USD | -75.02% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 83.755% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | -37.904% |
| Zura Bio Limited | -60.56 Million USD | 35.007% |
| PolyPid Ltd. | -20.26 Million USD | -94.256% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | -152.11% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | -37.904% |
| Instil Bio, Inc. | -146.12 Million USD | 73.062% |
| argenx SE | -216.02 Million USD | 81.779% |
| Immunome, Inc. | -28.27 Million USD | -39.231% |
| Compass Therapeutics, Inc. | -48.47 Million USD | 18.796% |
| Verona Pharma plc | -52.46 Million USD | 24.978% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | 58.467% |
| Shattuck Labs, Inc. | -87.61 Million USD | 55.074% |
| CervoMed Inc. | -2.17 Million USD | -1712.352% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | 67.8% |
| Plus Therapeutics, Inc. | -12.69 Million USD | -210.108% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 18.292% |
| Moolec Science SA | -52.07 Million USD | 24.414% |
| Enveric Biosciences, Inc. | -17.13 Million USD | -129.65% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | 69.812% |
| AnaptysBio, Inc. | -143.16 Million USD | 72.506% |
| Design Therapeutics, Inc. | -66.32 Million USD | 40.653% |
| Leap Therapeutics, Inc. | -80.98 Million USD | 51.397% |
| NeurAxis, Inc. | -6.66 Million USD | -490.622% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | -4.27% |
| Lumos Pharma, Inc. | -36.57 Million USD | -7.635% |
| Achilles Therapeutics plc | -70.44 Million USD | 44.121% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | 58.467% |
| 180 Life Sciences Corp. | -22.13 Million USD | -77.835% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | 775.25% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -1512.262% |
| Nutriband Inc. | -5.12 Million USD | -668.522% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | 64.134% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | 28.99% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | 22.133% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | 39.7% |
| MoonLake Immunotherapeutics | -54.1 Million USD | 27.256% |
| Palisade Bio, Inc. | -12.28 Million USD | -220.511% |
| Tourmaline Bio, Inc. | -45.37 Million USD | 13.254% |
| Beam Therapeutics Inc. | -156.47 Million USD | 74.844% |
| Neurogene Inc. | -52.28 Million USD | 24.718% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | 71.161% |
| AEON Biopharma, Inc. | -48.36 Million USD | 18.608% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | 57.683% |
| Sesen Bio, Inc. | -50.84 Million USD | 22.577% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | 51.958% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | -218.72% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 90.791% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | 62.583% |
| Athira Pharma, Inc. | -116.7 Million USD | 66.272% |
| Vaccinex, Inc. | -19.74 Million USD | -99.321% |
| HCW Biologics Inc. | -23.57 Million USD | -66.958% |
| XOMA Corporation | -39.36 Million USD | -0.0% |
| Nektar Therapeutics | -243.1 Million USD | 83.809% |
| Arvinas, Inc. | -394.8 Million USD | 90.03% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 20958.902% |
| Merus N.V. | -149.2 Million USD | 73.619% |
| Omega Therapeutics, Inc. | -93.49 Million USD | 57.897% |
| Quince Therapeutics, Inc. | -31.26 Million USD | -25.918% |
| Rezolute, Inc. | -68.42 Million USD | 42.473% |
| Clene Inc. | -43.24 Million USD | 8.971% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | -155.23% |
| BeyondSpring Inc. | -21.54 Million USD | -82.739% |
| Synlogic, Inc. | -55.16 Million USD | 28.642% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | -225.763% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | -269.874% |
| Peak Bio, Inc. | -1356.23 USD | -2902210.08% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | -21.244% |
| Krystal Biotech, Inc. | 17.9 Million USD | 319.85% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | 66.762% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 88.469% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | -754.501% |
| MannKind Corporation | 15.12 Million USD | 360.176% |
| Ikena Oncology, Inc. | -74.39 Million USD | 47.092% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | -212.57% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | 293.644% |
| Gossamer Bio, Inc. | -172.15 Million USD | 77.135% |
| CohBar, Inc. | -12.06 Million USD | -226.229% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | -54.306% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | -31.097% |
| Legend Biotech Corporation | -477.87 Million USD | 91.763% |
| Mural Oncology plc | -192.72 Million USD | 79.576% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 65.488% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -143.799% |
| Disc Medicine, Inc. | -91.02 Million USD | 56.757% |
| Champions Oncology, Inc. | -5.05 Million USD | -678.829% |
| REGENXBIO Inc. | -239.46 Million USD | 83.562% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | -267.245% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 29.403% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | -1.531% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | 65.106% |
| Vaxart, Inc. | -74.72 Million USD | 47.323% |
| PharmaCyte Biotech, Inc. | - USD | Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | -11.798% |
| Cellectis S.A. | -98.09 Million USD | 59.874% |
| Longeveron Inc. | -20.06 Million USD | -96.221% |
| Repare Therapeutics Inc. | -114.27 Million USD | 65.554% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 91.038% |
| Inozyme Pharma, Inc. | -74.81 Million USD | 47.385% |
| Revolution Medicines, Inc. | -430.58 Million USD | 90.858% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | -525.886% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | -27.844% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 47.229% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | 902.815% |
| Anixa Biosciences, Inc. | -10.96 Million USD | -258.979% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 100.855% |
| Denali Therapeutics Inc. | -179.97 Million USD | 78.129% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -41243.164% |
| Veru Inc. | -89.97 Million USD | 56.253% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | -46.447% |
| Cingulate Inc. | -22.95 Million USD | -71.497% |
| Passage Bio, Inc. | -98.34 Million USD | 59.974% |
| Context Therapeutics Inc. | -25.06 Million USD | -57.067% |
| Exicure, Inc. | -15.53 Million USD | -153.311% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 80.898% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | -6.453% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | -560.149% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | 76.635% |
| Nuvalent, Inc. | -149.49 Million USD | 73.669% |
| ABVC BioPharma, Inc. | -8.13 Million USD | -384.014% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | 54.174% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | -30.433% |
| OmniAb, Inc. | -49.73 Million USD | 20.85% |
| Anew Medical, Inc. | -1.3 Million USD | -2925.891% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | -218.36% |
| Lipocine Inc. | -16.32 Million USD | -141.149% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | 40.96% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | 47.025% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | -3.222% |
| G1 Therapeutics, Inc. | -39.01 Million USD | -0.892% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | -77.442% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 92.779% |
| Ocugen, Inc. | -64.82 Million USD | 39.281% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | 57.479% |
| Q32 Bio Inc. | -86.5 Million USD | 54.496% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | -132.54% |
| Alumis Inc. Common Stock | -156.89 Million USD | 74.911% |
| Equillium, Inc. | -12.13 Million USD | -224.287% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | 32.682% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -398.042% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | -108.695% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 15.699% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 62.987% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | -120.064% |
| Dominari Holdings Inc. | -22.44 Million USD | -75.41% |
| Edesa Biotech, Inc. | -8.19 Million USD | -380.602% |
| vTv Therapeutics Inc. | -25.41 Million USD | -54.895% |
| Bio-Techne Corporation | 326.66 Million USD | 112.05% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 89.772% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | 118.19% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | 69.977% |
| Candel Therapeutics, Inc. | -37.43 Million USD | -5.159% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 73.95% |
| Nkarta, Inc. | -120.48 Million USD | 67.329% |
| BioCardia, Inc. | -11.56 Million USD | -240.502% |
| Iterum Therapeutics plc | -34.58 Million USD | -13.829% |